Use of discriminant analysis in assessing pulmonary function worsening in patients with sarcoidosis by a panel of inflammatory biomarkers

Paone, Gregorino; Leone, Alvaro; Batzella, Sandro; Conti, Vittoria; Belli, F.; Marchis, Laura De; Mannocci, Alice; Schmid, Giovanni; Terzano, Claudio

doi:10.1007/s00011-012-0585-9

Cited by 10 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum levels of these biomarkers were said to reflect increased parenchymal infiltration and lymphocytic alveolitis in sarcoidosis and can thus serve as potential EBC biomarkers. Nonetheless, only a few have been shown to be sufficiently sensitive and specific [ 110 ].…”

Section: Exhaled Breath Condensate: Detection Of Immunological Marmentioning

confidence: 99%

Sarcoidosis: Immunopathogenesis and Immunological Markers

Loke

Herbert

Thomas

2013

International Journal of Chronic Diseases

View full text Add to dashboard Cite

Sarcoidosis is a multisystem granulomatous disorder invariably affecting the lungs. It is a disease with noteworthy variations in clinical manifestation and disease outcome and has been described as an “immune paradox” with peripheral anergy despite exaggerated inflammation at disease sites. Despite extensive research, sarcoidosis remains a disease with undetermined aetiology. Current evidence supports the notion that the immune response in sarcoidosis is driven by a putative antigen in a genetically susceptible individual. Unfortunately, there currently exists no reliable biomarker to delineate the disease severity and prognosis. As such, the diagnosis of sarcoidosis remains a vexing clinical challenge. In this review, we outline the immunological features of sarcoidosis, discuss the evidence for and against various candidate etiological agents (infective and noninfective), describe the exhaled breath condensate, a novel method of identifying immunological biomarkers, and suggest other possible immunological biomarkers to better characterise the immunopathogenesis of sarcoidosis.

show abstract

Section: Exhaled Breath Condensate: Detection Of Immunological Marmentioning

confidence: 99%

Sarcoidosis: Immunopathogenesis and Immunological Markers

Loke

Herbert

Thomas

2013

International Journal of Chronic Diseases

View full text Add to dashboard Cite

show abstract

“…The absence of a specific etiologic agent, together with histopathologic dependence and exclusion of multiple diseases often delays diagnosis (1)(2)(3)(4)(5)(6). Moreover, biomarkers lack accuracy to diagnose sarcoidosis and cannot reliably predict organ involvement, disease progression, and other clinical outcomes (7)(8)(9)(10). To satisfy diagnostic and prognostic needs, efforts have focused on identification of genes and products of cellular activity and metabolism (11)(12)(13)(14)(15)(16)(17).…”

mentioning

confidence: 99%

A Circulating MicroRNA Signature Serves as a Diagnostic and Prognostic Indicator in Sarcoidosis

Ascoli¹,

Huang²,

Schott³

et al. 2018

Am J Respir Cell Mol Biol

View full text Add to dashboard Cite

Micro-RNAs (miRNAs) act as post-transcriptional regulators of gene expression. In sarcoidosis, aberrant miRNA expression may enhance immune responses mounted against an unknown antigenic agent. We tested whether a distinct miRNA signature functions as a diagnostic biomarker and explored its role as an immune modulator in sarcoidosis. Expression of miRNAs from peripheral blood mononuclear cells from subjects that met clinical and histopathologic criteria for sarcoidosis were compared to those from matched controls in the ACCESS study. Signature miRNAs were determined by miRNA microarray analysis and validated by quantitative reverse transcription PCR (RT-qPCR). Microarray analysis identified 54 differentially expressed feature mature human miRNAs between groups. Significant feature miRNAs that distinguish sarcoidosis from controls were selected by use of probabilistic models adjusted for clinical variables. Eight signature miRNAs were chosen to verify the diagnosis of sarcoidosis in a validation cohort and distinguished sarcoidosis from controls with a positive predictive value of 88%. We identified both novel and previously described genes and molecular pathways associated with sarcoidosis as targets of these signature miRNAs. Additionally, we demonstrate that signature miRNAs (hsa-miR-150-3p and hsa-miR-342-5p) are significantly associated with reduced lymphocytes and airflow limitations, known markers of poor prognosis. Together, these findings suggest that a circulating miRNA signature serves as a non-invasive biomarker that supports the diagnosis of sarcoidosis. Future studies will test the miRNA signature as a prognostication tool associated with poor clinical outcomes in sarcoidosis.

show abstract

“…Clinical characteristics and prognosis greatly differ in subjects with sarcoidosis. Although several biomarkers were investigated to predict the disease activity or prognosis, no reliable biomarker has been established 5 , 35 , 36 . In the present study, subjects with active sarcoidosis showed a significant decrease in U-ATX levels compared to those with inactive sarcoidosis (Fig.…”

Section: Discussionmentioning

confidence: 99%

Urine autotaxin levels reflect the disease activity of sarcoidosis

Murakami

Tamada

Saigusa

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Since the clinical outcome of patients with sarcoidosis is still unpredictable, a good prognostic biomarker is necessary. Autotaxin (ATX) and phosphatidylserine-specific phospholipase A1 (PS-PLA1) function as main enzymes to produce lysophospholipids (LPLs), and these enzymes are attracting attention as useful biomarkers for several chronic inflammatory diseases. Here, we investigated the relationships between LPLs-producing enzymes and the disease activity of sarcoidosis. In total, 157 patients with sarcoidosis (active state, 51%) were consecutively enrolled. Using plasma or urine specimens, we measured the values of LPLs-producing enzymes. Urine ATX (U-ATX) levels were significantly lower in the active state compared to those in the inactive state, while the plasma ATX (P-ATX) and PS-PLA1 levels showed no significant difference between these two states. Concerning the comparison with existing clinical biomarkers for sarcoidosis, U-ATX showed a weak negative correlation to ACE, P-ATX a weak positive correlation to both ACE and sIL-2R, and PS-PLA1 a weak positive one to sIL-2R. Notably, only the U-ATX levels inversely fluctuated depending on the status of disease activity whether OCS had been used or not. These findings suggest that U-ATX is likely to be a novel and useful molecule for assessing the disease activity of sarcoidosis.

show abstract

Use of discriminant analysis in assessing pulmonary function worsening in patients with sarcoidosis by a panel of inflammatory biomarkers

Abstract: Our results show that a combinational approach could contribute to identifying individuals likely to experience pulmonary function worsening, thus helping to decide the correct therapeutic strategies.

Cited by 10 publications

References 36 publications

Sarcoidosis: Immunopathogenesis and Immunological Markers

Sarcoidosis: Immunopathogenesis and Immunological Markers

A Circulating MicroRNA Signature Serves as a Diagnostic and Prognostic Indicator in Sarcoidosis

Urine autotaxin levels reflect the disease activity of sarcoidosis

Contact Info

Product

Resources

About